NexOptic Announces Private Placement
NexOptic Technology Corp. (NXOPF) has announced a non-brokered private placement offering of up to 28,571,428 units at $0.035 per unit, aiming to raise up to $1,000,000. Each unit includes one common share and one warrant exercisable at $0.05 for 18 months. The company is streamlining operations by discontinuing relationships with semiconductor companies and closing its Korean subsidiary. Proceeds will support the development of AI data compression, video resolution technologies, and medical imaging enhancement software. The company plans to focus on leveraging its FDA-approved medical imaging device and enhancing NexCompress, its AI compression solution for security cameras and video streaming.
NexOptic Technology Corp. (NXOPF) ha annunciato un'offerta di collocamento privato non intermediato fino a 28.571.428 unità a $0,035 per unità, con l'obiettivo di raccogliere fino a $1.000.000. Ogni unità include un'azione comune e un warrant esercitabile a $0,05 per 18 mesi. L'azienda sta semplificando le operazioni interrompendo le relazioni con le aziende di semiconduttori e chiudendo la sua filiale coreana. I proventi supporteranno lo sviluppo di tecnologie di compressione dei dati AI, risoluzione video e software per il miglioramento dell'imaging medico. L'azienda prevede di concentrarsi sull'utilizzo del suo dispositivo di imaging medico approvato dalla FDA e sul miglioramento di NexCompress, la sua soluzione di compressione AI per telecamere di sicurezza e streaming video.
NexOptic Technology Corp. (NXOPF) ha anunciado una oferta de colocación privada no intermediada de hasta 28.571.428 unidades a $0,035 por unidad, con el objetivo de recaudar hasta $1.000.000. Cada unidad incluye una acción ordinaria y una opción de compra ejercitable a $0,05 durante 18 meses. La empresa está optimizando sus operaciones al interrumpir relaciones con empresas de semiconductores y cerrando su filial en Corea. Los ingresos respaldarán el desarrollo de tecnologías de compresión de datos AI, resolución de video y software de mejora de imagen médica. La empresa planea concentrarse en aprovechar su dispositivo de imagen médica aprobado por la FDA y mejorar NexCompress, su solución de compresión AI para cámaras de seguridad y transmisión de video.
NexOptic Technology Corp. (NXOPF)는 주당 $0.035에 최대 28,571,428개의 단위를 비공식적으로 사모할 것이라고 발표했으며, 목표로 하는 자금 조달은 최대 $1,000,000입니다. 각 단위는 하나의 보통주와 18개월 동안 $0.05에 행사할 수 있는 보증서를 포함합니다. 회사는 운영을 간소화하고 있습니다 반도체 회사와의 관계를 중단하고 한국 자회사를 폐쇄했습니다. 수익금은 AI 데이터 압축, 비디오 해상도 기술 및 의료 이미징 개선 소프트웨어 개발을 지원합니다. 회사는 FDA 승인 의료 이미징 장치를 활용하고 보안 카메라 및 비디오 스트리밍을 위한 AI 압축 솔루션인 NexCompress를 개선하는 데 주력할 계획입니다.
NexOptic Technology Corp. (NXOPF) a annoncé une offre de placement privé non intermédié allant jusqu'à 28.571.428 unités à 0,035 $ par unité, visant à lever jusqu'à 1.000.000 $. Chaque unité comprend une action ordinaire et un bon de souscription exerçable à 0,05 $ pendant 18 mois. La société rationalise ses opérations en mettant fin à ses relations avec des entreprises de semi-conducteurs et en fermant sa filiale coréenne. Les produits serviront à soutenir le développement de la compression des données par IA, des technologies de résolution vidéo et d'un logiciel d'amélioration de l'imagerie médicale. L'entreprise prévoit de se concentrer sur l'exploitation de son dispositif d'imagerie médicale approuvé par la FDA et d'améliorer NexCompress, sa solution de compression IA pour les caméras de sécurité et le streaming vidéo.
NexOptic Technology Corp. (NXOPF) hat eine nicht vermittelte Privatplatzierung von bis zu 28.571.428 Einheiten zu je 0,035 $ pro Einheit angekündigt, mit dem Ziel, bis zu 1.000.000 $ zu sammeln. Jede Einheit umfasst eine Stammaktie und ein Warrant, das für 18 Monate zu 0,05 $ ausgeübt werden kann. Das Unternehmen optimiert seine Abläufe, indem es Beziehungen zu Halbleiterunternehmen beendet und seine koreanische Tochtergesellschaft schließt. Die Erlöse werden die Entwicklung von KI-Datenkompression, Videoauflösungs-technologien und Software zur Verbesserung der medizinischen Bildgebung unterstützen. Das Unternehmen plant, sich darauf zu konzentrieren, sein von der FDA genehmigtes medizinisches Bildgebungsgerät zu nutzen und NexCompress, seine KI-Kompressionslösung für Sicherheitskameras und Video-Streaming, zu verbessern.
- FDA approval obtained for medical imaging device
- Raising up to $1,000,000 through private placement
- Operational cost reduction through subsidiary closure and partnership terminations
- Potential shareholder dilution from private placement
- Working capital deficiencies mentioned in the PR
- Discontinuation of semiconductor partnerships may limit growth opportunities
VANCOUVER, BC / ACCESSWIRE / November 7, 2024 / NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE:NXO)(OTCQB:NXOPF)(FSE:E3O1), a company developing cutting-edge AI and imaging technologies, is pleased to announce that, further to its news release dated October 24, 2024, it intends to complete a non-brokered private placement of up to 28,571,428 units (each, a "Unit") of the Company, at a price of
Each Unit will be comprised of one common share in the capital of NexOptic (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant will be exercisable for one Common Share at a price of
In the continuation of streamlining its operations, NexOptic has opted to discontinue its affiliations with several third-party companies including semiconductor companies. The Company may reassess these relationships in the future. Additional cost saving decisions include closing the Company's Korean subsidiary, NexOptic Asia. The new direction of NexOptic will be to leverage its success in an FDA approved medical imaging device that significantly increases image resolution. Enhancements to NexOptic's AI compression offering, NexCompress, is also planned. NexCompress can offer significant cost and energy savings to the security camera and video streaming industries. Announcements related to sales and marketing appointments and product advancements are anticipated by the Company. Please see additional details on the Company's go forward plans in the "Corporate Update" section of the Company's news release dated October 24, 2024.
NexOptic intends to use the proceeds from the Offering to advance its data compression and video resolution artificial intelligence ("AI") and its medical imaging enhancement software technologies, marketing and sale of the Company's products, investor relations, and for general corporate working capital purposes, including any current working capital deficiencies. The Company expects to allocate the net proceeds of the Offering equally to the foregoing uses, other than with respect to investor relations activity, which will be limited to
The Offering is subject to the receipt of all regulatory approvals including the approval of the TSXV. All securities issued under the Offering will be subject to a hold period expiring four months and one day from the date of issuance. The Offering is expected to close in one or more tranches. In connection with the Offering, the Company may pay finder's fees on the Units sold in an amount equal up to
Insiders of the Company are anticipated to subscribe for Common Shares under the Offering. The insiders' participation in the Offering constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Such participation is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities anticipated to be acquired by insiders, nor the consideration for the securities paid by such insiders, exceed
What You Need to Know About NexOptic
NexOptic is an innovative imaging AI company headquartered in Vancouver, Canada offering world-leading patented and patent pending AI solutions for imaging known as ALIIS™ (All Light Intelligent Imaging Solutions) and NexCompress.
For more information about NexOptic Technology Corp., please visit the Company's website at www.nexoptic.com
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified by the use of terminology such as "plans," "expects," "estimates," "intends," "anticipates," "believes" or variations of such words, or statements that certain actions, events or results "may," "could," "would," "might," "will be taken," "occur," or "be achieved." Forward-looking statements in this news release include, without limitation, expectations relating to the Offering, including receipt of Exchange approval for the Offering, its ability to close the Offering in whole or in part or at all, and the proposed use of proceeds of the Offering, as well as statements with respect to the Company's new direction and future plans. The intended use of the proceeds of the Offering by the Company might change if the board of directors of the Company determines that it would be in the best interests of the Company, and the proposed allocations of the use of proceeds may change if the Forward-looking statements involve risks, uncertainties and other factors disclosed under the heading "Risk Factors" and elsewhere in NexOptic's filings with Canadian securities regulators, that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although NexOptic believes that the assumptions and factors used in preparing these forward-looking statements are reasonable based upon the information currently available to management as of the date hereof, actual results and developments may differ materially from those contemplated by these statements. Readers are therefore cautioned not to place undue reliance on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether because of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
On behalf of the board of directors
Chief Executive Officer - Paul McKenzie
Tel: +1 (604) 669-7330 ext. 1
Email: admin@nexoptic.com
SOURCE: NexOptic Technology Corp.
View the original press release on accesswire.com
FAQ
What are the terms of NexOptic's (NXOPF) November 2024 private placement?
How will NexOptic (NXOPF) use the proceeds from its 2024 private placement?
What operational changes is NexOptic (NXOPF) implementing in 2024?
